Patients With Pancreatic Cancer With Synchronous Liver Oligometastasis Show a Significant Long‐Term Survival Benefit From Resection Under Specific Conditions: A Multicenter National Cohort Study
Year: 2025
Type: article
Study design: Observational Study
Abstract: BACKGROUND: In this study, we investigated the criteria that predict the long-term survival benefits after surgical resection in patients with pancreatic cancer accompanied by liver oligometastasis. METHODS: In total, 60 patients from 34 high-volume Japanese centers who underwent surgical resection for liver oligometastasis between 2005 and 2020 were included. Univariate and multivariate methods of survival analyses were performed. All patients were followed up for at least 36 months. RESULTS: Overall survival (OS) was significantly longer in the preoperative chemotherapy group than in the up-front surgery group (37.4 vs. 20.4 months, p = 0.001). In the operation with preoperative chemotherapy group, a complete response was observed in eight patients (28.6%). The 1-, 3-, and 5-year OS rates were 92.9%, 50.0%, and 35.7%, respectively. The multivariate analysis showed that low CA19-9 (< 100 U/mL; HR: 0.25; 95% CI: 0.06-0.96; p = 0.043), low CEA (< 5 U/mL; HR: 0.14; 95% CI: 0.04-0.48; p = 0.002), and resectable (R) or borderline resectable pancreatic cancer invading the portal vein (BR-PV) status (HR: 0.19; 95% CI: 0.07-0.51; p < 0.001) were positive prognostic factors. The median OS of the patients who met all three criteria was 106.6 months. CONCLUSION: Preoperative chemotherapy is essential for the treatment of liver oligometastases. Despite the high recurrence rates, patients who met the specific criteria have a favorable prognosis with liver resection.
DOI: 10.1002/jhbp.12181
Authors: Kohei Nakata, Yoshihiro Miyasaka, Takeaki Ishizawa, Masayuki Ohtsuka, Masamichi Mizuma, Sohei Satoi, Masaaki Hidaka, Shuji Suzuki, Hiroshi Kurahara, Chie Kitami, Satoshi Hirano, Dongha Lee, Saiho Ko, Munenori Tahara, Isaku Yoshioka, Kenjiro Date, Kazuyuki Nagai, Goro Honda, Shugo Mizuno, Kenichi Hakamada, Yasuro Futagawa, Shigeru Marubashi, Hiroshi Yoshida, Akihiko Horiguchi, Yasuo Hosouchi, Masafumi Imamura, Naoto Gotohda, Hiroaki Nagano, Masaji Tani, Takeshi Sudo, Teijiro Hirashita, Junichi Arita, Katsutoshi Murase, Ken Fukumitsu, Toshiki Rikiyama, Teruyuki Usuba, Toshiya Abe, Masafumi Nakamura, Itaru Endo
Institutions: Kyushu University, Fukuoka University, Osaka Metropolitan University, Chiba University, Tohoku University, Kansai Medical University, Shimane University, University of Shimane, Tokyo Medical University, Tokyo Medical University Ibaraki Medical Center, Kagoshima University, Nagaoka Chuo General hospital, Hokkaido University, Kindai University, Nara Prefecture General Medical Center, Sapporo Kosei General Hospital, University of Toyama, Kitakyushu Municipal Medical Center, Kyoto University, Tokyo Women's Medical University, Institute of Gastroenterology, Tokyo Women's Medical University, Mie University, Mie University Hospital, Hirosaki University, Jikei University School of Medicine, Fukushima Medical University, Iwaki City Medical Center, Fujita Health University Bantane Hospital, Gunma Saiseikai Maebashi Hospital, Sapporo Medical University, National Cancer Centre Japan, National Cancer Center Hospital East, Yamaguchi University, Shiga University of Medical Science, Kure Medical Center, Oita University, Akita University, Gifu University, Kyoto Katsura Hospital, Jichi Medical University, Jichi Medical University Saitama Medical Center, Saitama Medical Center, Saitama Medical University, Saitama Medical University, Katsushika Medical Center, Yokohama City University
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,700
OpenAlex ID: W4412379545